|
Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
ISSN: 1596-5996 EISSN: 1596-5996
Vol. 16, No. 6, 2017, pp. 1325-1329
|
Bioline Code: pr17169
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Tropical Journal of Pharmaceutical Research, Vol. 16, No. 6, 2017, pp. 1325-1329
en |
Benefits afforded by combined temozolomide, radiation and stem cell strategy for glioma therapy
Li, Bin; Wang, Fei & Hai, Jian
Abstract
Purpose: To compare the efficacy of temozolomide, radiation and stem cell therapy in glioma
management.
Methods: A total of 112 patients with glioblastoma were divided into four groups, each of 28 patients.
Group I received daily temozolomide at 150 mg/m2; Group II radiotherapy of 30.0 Gy; Group III
mesenchymal stem cells only; and Group IV all three treatments (temozolomide 100 mg/m2 + 30.0 Gy of
radiotherapy + two infusions of mesenchymal stem cells, weekly for 3 weeks. All patients were
assessed 1, 6, and 12 months following the conclusion of treatment.
Results: Of Group I patients, the maximum improvement in tumor diameter was 58 % but only 28 %
ultimately survived. Of Group II patients, the maximum improvement was 49 % but, again, only 28 %
survived (p = 0.06 for both groups). Of Group III patients, the maximum improvement was 71 % and 40
% survived. Of Group IV patients, who received all three treatments, the maximum improvement was 80
%. The survival rate was 60 %.
Conclusion: Stem cells improved patient outcomes and may be a useful alternative therapy for glioma.
Keywords
Glioma therapy; Temozolomide; Stem cells; Prognosis; Radiotherapy
|
|
© Copyright 2017 - Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. Alternative site location: http://www.tjpr.org
|
|